Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 5/20 | 0.66 |
| ▸ | RARB | P10826 | 5/20 | 0.66 |
| ▸ | RARG | P13631 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 7/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369431 | 0.94 | RARA (0.67) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL996174 | 0.93 | RARA (0.65) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6368666 | 0.92 | RARA (0.64) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL2682763 | 0.92 | RARA (0.68) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL2683146 | 0.90 | RARA (0.66) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL16272969 | 0.90 | RARA (0.70) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6369553 | 0.90 | RARB (0.62) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6368948 | 0.90 | RARB (0.62) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6368925 | 0.90 | CYP3A4 (0.62) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL6369204 | 0.89 | CYP3A4 (0.65) | RARARARBRARGCYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453746-A1 | TAZAROTENE DERIVATIVES | Stiefel Laboratories, Inc. (US) | 2012-05-23 | — | — | EP | claimed |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2012-05-10 | — | — | US | claimed |
| WO-2011009023-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. (US) | 2011-01-20 | — | — | WO | claimed |
| US-9062037-B2 | Tazarotene derivatives | STIEFEL LABORATORIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062037-B2 | Tazarotene derivatives | STIEFEL LABORATORIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062037-B2 | Tazarotene derivatives | STIEFEL LABORATORIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2014-12-04 | — | — | US | disclosed |
| EP-2453746-A1 | TAZAROTENE DERIVATIVES | Stiefel Laboratories, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2011009023-A1 | TAZAROTENE DERIVATIVES | STIEFEL LABORATORIES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357672-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARA 2/4885RARB 5/4885RARG 6/4885 |
| US-20140357669-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARA 2/4885RARB 5/4885RARG 6/4885 |
| US-20120115909-A1 | TAZAROTENE DERIVATIVES | RXRA, RARA, RXRB | RARA 2/4885RARB 5/4885RARG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.